RecruitingNot applicableNCT05714930
LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
Studying Systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Heinrich-Heine University, Duesseldorf
- Principal Investigator
- Matthias Schneider, MDHeinrich-Heine University, Duesseldorf
- Intervention
- Treat-to-target as a new treatment concept(other)
- Enrollment
- 606 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (14)
- University Clinic Freiburg, Freiburg im Breisgau, Baden-Wurttemberg, Germany
- University Clinic Heidelberg, Heidelberg, Baden-Wurttemberg, Germany
- University Clinic Erlangen, Erlangen, Bavaria, Germany
- LMU Munich, Munich, Bavaria, Germany
- University Clinic Frankfurt, Frankfurt am Main, Hesse, Germany
- Medical University Hannover, Hanover, Lower Saxony, Germany
- University Clinic Düsseldorf, Düsseldorf, North Rhine-Westphalia, Germany
- Kliniken Essen Mitte, Essen, Essen, North Rhine-Westphalia, Germany
- Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Herne, North Rhine-Westphalia, Germany
- University Clinic Münster, Münster, North Rhine-Westphalia, Germany
- University Clinic Mainz, Mainz, Rhineland-Palatinate, Germany
- University Medical Center TU Dresden, Dresden, Saxony, Germany
- Charité - Berlin University of Medicine, Berlin, Germany
- UKSH Campus Kiel, Kiel, Germany
Collaborators
University Hospital Heidelberg · German Diabetes-Center, Leibniz-Institut in Düsseldorf · Lupus Erythematodes-Selbsthilfegemeinschaft e.V.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05714930 on ClinicalTrials.govOther trials for Systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07107659Safety and Efficacy of ONT01 in LupusHospital for Special Surgery, New York
- RECRUITINGNANCT07558850Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune DiseasesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNCT06948110Deciphering the Genetic Architecture of Autoimmune DiseasesNational Human Genome Research Institute (NHGRI)
- RECRUITINGPHASE2NCT07409181A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Boehringer Ingelheim
- RECRUITINGPHASE3NCT07332481A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEMD Serono Research & Development Institute, Inc.
- RECRUITINGEARLY PHASE1NCT07526350MTS109 in Patients With Refractory Autoimmune DiseasesShanghai Changzheng Hospital
- RECRUITINGEARLY PHASE1NCT07490041Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic DiseasesThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNANCT07470151Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology